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I N T R O D U C T I O N
Single-isomer dru g s -m o re appropriately termed singleenantiomer drugs-contain only one of the two mirro r-i m a g e f o rms of a chiral molecule (see Gal, pp [8] [9] [10] [11] [12] [13] . Interest in such drugs has intensified greatly during the past quart e rc e n t u ry, and a great deal of re s e a rch on the basic and clinical aspects of single-isomer drugs has shown that the two m i rro r-image forms often differ significantly in their eff e c t s . As a result, the consensus today is that in most cases a singleisomer form of chiral drugs is advantageous over the corresponding racemic mixture. Many single-isomer compounds a re in various stages of development as new therapeutic agents, and many others are being studied in re s e a rch laboratories for their pharmacological potential.
The purpose of the present article, then, is to survey interesting new single-isomer candidates that are, at the time of this writing, in more advanced stages of development and that have a good probability of reaching the clinic. It is re c o mmended that the companion article on the fundamentals of the phenomenon of single-isomer compounds be reviewed as an aid to the appreciation of the nature and terminology of these agents.
A BRIEF HISTORY OF SINGLE-ISOMER DRUGS
Single-isomer drugs are not new; indeed, some of the oldest drugs in use have been single isomers. These drugs were first used as crude plant extracts, and subsequently their medicinal pro p e rties were discovered by modern medicine. For example, ephedrine has been used in China for 5,000 years as an extract from ephedra species ("Ma Huang").
1 P u re ephedrine substance was isolated in 1887 and intro d u c e d into We s t e rn medicine in 1925. 1 Another example is morphine, the main active alkaloid in opium, an extract of poppy (Papaver somniferu m) seed capsules. The first credible re f e rence to opium was in the writings of Theophrastus, the Gre e k philosopher and pupil of Aristotle, in the third century B.C., 2 but opium may have been used by the ancient Egyptians as early as 3,500 years ago, although this point is a matter of d e b a t e . 3 P u re morphine substance was isolated in 1805, and by the middle of the 19th century it came into use as the alkaloid instead of the crude extract. 2 T h e re are many other centuries-old single-isomer drugs still in use, eg, quinine, cocaine, digoxin, etc.
By the end of the 20th century, about one half of all dru g s in use were chiral, and about 50% of such drugs were used in single-isomer form, the other half being racemic. An intere s ting aspect of the introduction of chiral drugs was pointed out by Ariens and Wuis, who, in 1987 , found that 98% of chiral d rugs obtained from natural sources (or directly derived fro m natural compounds) were marketed in single-isomer form , while only 12% of synthetic chiral drugs were single isomers. 4 The interpretation is clear: since nature usually provides chiral substances in single-isomer form, drugs from natural s o u rces were introduced almost always as single isomers; on the other hand, when chemical synthesis was re q u i red to obtain chiral drugs, the more easily accessible and cheaper racemic form was chosen.
In the past ca. 25 years, intensive re s e a rch eff o rts have been exerted to elucidate the role of chirality in drug action and disposition. 5 In general, it has become abundantly clear that chirality often has an important role in shaping the pharmacodynamic and/or pharmacokinetic behavior of chiral d rugs and that the two enantiomers of a racemate often diff e r s i g n i f i c a n t l y, sometimes even drastically, in their pharm a c ological and/or pharmacokinetic behavior. 5 As a result, re g u l at o ry agencies, academia, and the pharmaceutical industry took up the question of the development of new drugs as single isomers versus racemates.
The debate culminated with the United States Food and D rug Administration (FDA) issuing new guidelines in May 1992 on the role of stereoisomerism in new-drug developm e n t .
6 Similar guidelines were also issued by other dru gre g u l a t o ry agencies around the world. In essence, the new guidelines strongly encourage the development of singleisomer drugs and discourage new racemates, although the latter are not banned and new racemic drugs can be introduced in certain circumstances. However, the overall eff e c t of the new re g u l a t o ry climate has been to stimulate the development of single-isomer drugs with a near-c o m p l e t e exclusion of new racemates.
This new re g u l a t o ry climate is already making itself felt, and the development and marketing of single-isomer dru g s has greatly accelerated during the last ca. 10 years, to the point that in 1999 the worldwide sale of single-isomer dru g s topped the $100 billion mark, re p resenting appro x i m a t e l y one third of total drug sales. 
SINGLE-ISOMER DRUG C A N D I D ATES IN DEVELOPMENT
As discussed above, most new chiral drugs will undoubtedly be developed in single-isomeric form. It is also clear that re s e a rch activities both in academic and industrial laboratories on the detailed role of chirality in the actions and disposition of chiral drugs will continue unabated. Such re s e a rch is of fundamental importance for the rational design and development of safe and effective single-isomer drugs. It is important to note, however, that for the foreseeable future many of the established racemic drugs will continue to be used in the racemic form .
The development of new single-isomer drugs relies, in general, on the same scientific and technological foundations n e c e s s a ry for the development of any new drug. However, t h e re are certain branches of biomedical science and technology that are specific underpinnings of the development of single-isomer agents. It goes without saying that understanding the three-dimensional aspects of the interaction of drugs with their target receptors is of paramount importance if we are to design safe and effective single-isomer agents. A variety of a p p roaches are used in studying the thre e -d i m e n s i o n a l details of dru g -receptor interactions, but the recent advances in molecular biology and in computational methodologies are p roviding great power for such investigations. 8 Access to a l a rge variety of single-isomer drugs has become possible as a result of the considerable advances of recent decades in synthetic organic chemistry and in combinatorial chemistry. F i n a l l y, advances in analytical methodology based on enantioselective chromatography permit isomer-specific measurement of drugs in biological fluids, a pre requisite for the development of single-isomer agents. P h a rmacological, pharmacokinetic, and toxicological considerations suggest that, as a generalization, the single enantiomer may possess one or more of the following potential advantages over the racemic mixture: reduced dosage; reduced adverse effects, including fewer drug interactions; i m p roved therapeutic efficacy; better-understood and simpler p h a rmacology; clearer pharmacokinetics; better-defined re l ationship between serum drug concentration and therapeutic/toxic effects. Naturally, not every one of these potential benefits is realized in every case, and in this context each new single-isomer drug candidate must be considere d on its own merits. Furt h e rm o re, and import a n t l y, exceptions to the generalization that a single isomer is better than the racemate do exist (see below).
The survey that follows focuses primarily on single-isomer agents that are not yet approved in the US (at the time of writing) but that are relatively well advanced in the dru g -d e v e l o pment process. However, a few compounds that are not as far along the process will also be mentioned when such agents a re of particular interest or illustrate an important principle. One unavoidable handicap in a survey of new drugs not yet a p p roved is that the information available on their pharm ac o l o g y, pharmacokinetics, and clinical aspects is at times limited. It should also be pointed out that since the number of single-isomer new-drug candidates is very large, the survey is necessarily not comprehensive. Thus, only a selection of agents can be discussed, and while an eff o rt was made to cover a variety of therapeutic areas and agents, to some extent the choices reflect the author's interests and bias.
In general, the new drug candidates in development may be loosely divided into two types: (1) compounds derived fro m n a t u re or closely related to natural products, such as stero i d s , alkaloids, antibiotics, peptides, etc. These are often larg e molecules containing multiple (>3) chiral centers, and are obtained directly from natural sources or are chemically modified derivatives of compounds from nature; some, however, may be entirely synthetic; and (2) other, typically smaller molecules not directly connected to compounds from n a t u re , often with few (1-3) chiral centers and usually totally synthetic. The borderline between the two groups, however, is not sharp and overlap is not infrequent, eg, some natural products may only have a few chiral centers, while some synthetic drugs may be rather large and have multiple chiral centers.
New single-isomer drugs are created via one of three available mechanisms: (1) the chiral switch; (2) the chiral metashift; or (3) new single-isomer chemical entity.
The Chiral Switch
In a chiral switch (CS), one of the two enantiomers fro m an existing racemic drug is developed as a new drug. The new single-isomer agent may be for the same indication as the parent racemate or for a diff e rent indication. The rationale for a CS is, of course, the advantage obtained by using a single isomer instead of the racemate. With the recent and c u rrent intense interest in single-isomer drugs a number of CSs have been implemented and many more CS candidates a re in development.
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Recently implemented examples include the antibacterial agent levofloxacin (from racemic ofloxacin); levosulpiride ( f rom racemic sulpiride) available in some European countries but not in the US; the anesthetic agent levobupivacaine ( f rom racemic bupivacaine); the analgesic/anti-inflammatory d e x k e t o p rofen (from racemic ketoprofen); the bro n c h o d i l a t o r l e v a l b u t e rol (from racemic albuterol); the anesthetic (S) -k e t amine (from racemic ketamine) available in Germany; the analgesic and anti-inflammatory dexibuprofen (from racemic i b u p rofen) available in several European countries but not in the US, etc. It is notewort h y, however, that CSs were practiced long before the current era of intensive focus on single-isomer therapeutics. For example, several decades ago the intro d u ction of the racemic oral contraceptive norg e s t rel was followed some years later by the marketing of its active single-isomer f o rm levonorg e s t rel, and both drugs are still available today. The theoretical advantages of single-isomer drugs are generally accepted and the benefits of many of the implemented CSs are clear; however, confirmation of the advantages of some of the recent CS drugs in clinical practice will have to await more extensive clinical experience.
Not surprisingly, not all CSs are successful. For example, dilevalol (a single isomer from the antihypertensive agent labetalol, a mixture of two racemates, ie, four stere o i s o m e r s ) was withdrawn because of hepatotoxicity 1 2 ; the single-isomer a n t i a rrhythmic agent dexsotalol (from racemic sotalol) failed a major clinical trial because of a high mortality rate 1 3 ; the development of the antidepressant (R)-fluoxetine (fro m racemic fluoxetine) was halted due to cardiotoxicity at higher d o s e s . 1 4 It is important to note that in all of these cases the racemic parent continues to be available.
T h e re are several potential reasons for such CS failure s , but one significant factor, often unappreciated, is the nature of racemic mixtures: when the two isomers are used together they may interact (ie, compete with or inhibit each other) at various critical sites (eg, at receptors, enzyme active sites, on binding proteins), and such interactions render the racemate m o re complex than a simple linear combination of the two isomers. Recognizing the presence of and predicting such interactions are not straightforw a rd, and it is not surprising t h e re f o re that in some instances the single isomer displays "unexpected" behavior when it is separated from the mixture and used alone.
Another reason for the failure of the single isomer in a CS may be the independent protective effects provided by the other isomer present in the racemate. For example, it has been suggested that the better safety margin of racemic sotalol over dexsotalol may be due to the β-blocking effects of the racemate (provided by levo-sotalol). 1 5 Overall, these phenomena are an expression of the pharmacological complexities of drug mixtures and do not negate the potential advantages of single-isomer agents as a general pro p o s i t i o n , but they do emphasize the importance of good basic and clinical re s e a rch necessary to elucidate such complexities.
An interesting and important fallout of the new climate favoring single isomers merits attention. In the past, the racemate was first developed, and the single isomer came later, if at all. To d a y, however, the scenario is diff e rent: hencefort h most new chiral drugs will be developed from the outset in single-isomer form. In practice, then, a new racemic compound will be separated into the two isomers very early in the development process, and the latter will be evaluated individually for a decision on the isomer to be developed as the new single-isomer drug candidate. If the isomer selected eventually shows unacceptable adverse effects, its development will be halted. However, in such a case, ie, after the failure of the single isomer, no pharmaceutical company would even remotely contemplate to undertake the development of the racemate as a potentially safer drug (in what might be called a " reverse CS"). Thus, in re f e rence to the above-mentioned failed CS of the antidepressant (R)-fluoxetine, if the development of fluoxetine were initiated today, it is clear that after the initial finding that the single isomer (R)-fluoxetine is cardiotoxic, racemic fluoxetine would not be brought to the market. Considering that racemic fluoxetine (Prozac) has been an i m p o rtant and successful drug, the conclusion is clear: potentially useful and safe racemic drugs may not be developed today because of the emphasis on single-isomer agents. This loss must, however, be weighed against the potential benefits of single-isomer agents.
Drugs in Development Via CSs
Many new CSs, in a variety of therapeutic areas, are in d e v e l o p m e n t .
7 , 9 -1 1 An example is oxybutynin, an antimuscarinic and antispasmodic agent used for the treatment of urin a ry incontinence. The drug is used as the racemic mixture ( D i t ropan), and the S-enantiomer (Figure 1 ) is currently in development as a single-isomer agent for the treatment of urin a ry incontinence. 1 6 It has been suggested that the re l a t i v e l y weak antimuscarinic activity of (S)-oxybutynin may translate into a lower incidence of antimuscarinic side eff e c t s , 1 7 eg, dry mouth and blurred vision. (S)-Oxybutynin has completed Phase II clinical studies.
A well-advanced CS drug candidate is escitalopram ( F i g u re 1), the single-isomer version of the racemic antidep ressant citalopram (Celexa). Citalopram is a selective serotonin reuptake inhibitor (SSRI), and it has been re p o rt e d that the SSRI activity resides essentially exclusively in the S-enantiomer of the racemate, ie, escitalopram. 1 8 It would thus appear that the development of the pure active (singleisomer) form as a drug in its own right is indeed a logical step. In addition, in vitro studies of the cytochro m e -P 4 5 0 (CYP) mediated metabolism of escitalopram have led to the conclusion that the drug is unlikely to become involved in CYP-based drug interactions. 1 9 A selection of other CSs re p o rted in pro g ress are shown in the Table. As seen in the table, a variety of therapeutic are a s a re addressed by these agents. It should be emphasized that not necessarily all the drugs in development in CSs will actually reach the clinic, but clearly many will and the CS sce-nario is a viable mechanism for the introduction of new single-isomer dru g s .
The Chiral Metashift (CM)
Many drugs are biotransformed to metabolites whose molecules are chiral. In a CM the chiral metabolite is developed in single-isomer form as a drug in its own right. As in CSs, the rationale is that the new drug has advantages over the parent, in terms of efficacy and/or adverse effects. As in CSs, the new drug may be for the same indication as the parent or for a diff e rent indication. The parent drug in a CM may be racemic, single-isomeric, or even non-chiral, but the metabolite is chiral and is developed as a new drug in single-isomer form.
The CM scenario has been little used and is only now beginning to receive significant attention. Active metabolites may re p resent an unexploited source of new drugs, since in many cases the metabolic fate of drugs and the activity of metabolites have not been determined. Furt h e rm o re, in many cases (eg, the N-demethylated metabolites of N-methylated d rugs), the metabolites are likely to have a longer elimination and reduced toxicity. 9 An early attempt at a CM involved nicotine (a single-isomer drug) and its major metabolite, the single-isomer compound (S)-cotinine. The latter was patented in the mid-1960s as a treatment for depression, but was not developed. In the 1990s, cotinine was patented as an aid in smoking cessation, but subsequent clinical trials demonstrated that it was not e ffective in that indication.
2 0 M o re recently (S) -n o rn i c o t i n e , another single-isomer metabolite of nicotine, has been suggested, based on animal studies, to be potentially useful in smoking cessation. 2 1 Drugs in Development via CMs C u rre n t l y, several new single-isomer CM drugs are in development. Racemic cisapride (Propulsid, Figure 2 ) is a g a s t rointestinal prokinetic agent associated with potentially l i f e -t h reatening cardiac arrhythmias in certain situations such as accumulation of the drug (eg, via dru g interactions), the presence of other drugs that prolong the QT interval, or other diseases that may predispose the patient to arrh y t h m i a s . 22 Among the metabolites of cisapride a re the N-dealkylated compounds (+)-and (-)-norc i s a p r i d e ( F i g u re 2). (+)-Norcisapride, an active metabolite, is reported to be considerably safer than the parent in terms of cardiotoxicity and is in development as a new singleisomer drug. 
TABLE. NEW SINGLE-ISOMER DRUGS REPORTED IN

metabolites (R) -( + ) -didesmethylsibutramine and (S) -( -) -d i d e s m e t h y l s i b u t r a m i n e .
P h a rmacological studies of the two isomeric metabolites have found significant diff e rences in their ability to inhibit the reuptake of dopamine, norepinephrine, and serotonin, and the R-enantiomer was suggested to be a potentially advantageous agent for the treatment of obesity and depre s s i o n . 2 3 F u rt h e rm o re, Sepracor company literature indicates that the other metabolite isomer, (S)-(-)-didesmethylsibutramine, is in development for sexual dysfunction and stress urinary incontinence, but few details are available.
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FIGURE 2. THE STRUCTURES OF THE TWO ISOMERS IN RACEMIC CISAPRIDE AND OF THE TWO ISOMERS OF THE METABOLITE NORCISAPRIDE
The arrows in the structure of norcisapride indicate the atom from which the metabolic biotransformation removed a group. One of the two isomers of norcisapride, (+)-norcisapride (ie, dextro-norcisapride), is in development as a new drug via a chiral metashift, but it is not known which of the two structures it is. 
The two isomers of norcisapride
The two isomers contained in racemic cisapride
As we have seen, relatively few CM drugs are in development, but it is safe to predict that CM will be incre a s i n g l y used in the future as a mechanism for the identification and development of new single-isomer dru g s .
THE NEW SINGLE-ISOMER CHEMICAL ENTITY (NSICE)
In normal drug development, the term new chemical entity (NCE) refers to a new chemical compound for a given indication. For the purposes of the present discussion, new singleisomer chemical entity (NSICE) is defined as a new single-isomer drug candidate that is the result of neither a CS nor a CM. Thus, a NSICE may be an entirely new compound or it may be a known molecule that is being considered for development for a new indication.
A large number of NSICEs are at various stages of dru g development, from pre-clinical laboratory studies to late clinical testing phases just prior to application to FDA for a p p roval. Furt h e rm o re, a large variety of chemical stru c t u re s and therapeutic areas are encompassed by these singlei s omer drug candidates. Several mechanisms for the identification of new candidates are available, eg, systematic s t ru c t u re -a c t i v i t y -relationship studies; modification of lead compounds obtained from natural sources or identified fro m other existing agents; combinatorial synthesis; and computeraided drug design.
The large number of NSICEs precludes a compre h e n s i v e review of such drug candidates in the present forum and only a small fraction of the many compounds in development can be discussed here. Nevertheless, it is hoped that this surv e y of re p resentative NSICEs will provide a flavor of the variety of compounds and therapeutic areas involved.
DRUGS IN DEVELOPMENT AS NSICEs
C a rdiovascular diseases are a major target area for newd rug development, and single-isomer agents are well re p resented in this field. For example, rosuvastatin (ZD4522, F i g u re 4) is a new "statin" drug, ie, an inhibitor of HMG-CoA reductase indicated for the treatment of hyperc h o l e st e rolemia. Results of Phase III clinical trials of ro s u v a s t a t i n w e re presented in early 2001. 
FIGURE 3. THE SINGLE-ISOMER DRUG CANDIDAT E (S)-DESMETHYLZOPICLONE, A META B O-LITE OF THE S-ISOMER OF ZOPICLONE, AND THE TWO ISOMERS OF ZOPICLONE
The arrow in the structure of the metabolite indicates the site from where the methyl group was removed in the biotransformation. The letters R and S in the structure of zopiclone refer to the three-dimensional configuration. 
FIGURE 4. SOME SINGLE-ISOMER CARDIOVA S C UL A R DRUGS IN DEVELOPMENT AS NEW SINGLE-ISOMER CHEMICAL ENTITIES
The letters R and S indicate the configurations in the molecules. 
FIGURE 5. SOME SINGLE-ISOMER ANTI-INFECTIVE AGENTS IN DEVELOPMENT AS NEW SINGLE-ISOMER CHEMICAL ENTITIES
The arrows pointing to the amino and hydroxy group in DAPD and diocolane guanine, respectively, indicate the site of biotransformation catalyzed by adenosine deaminase.The letters R and S indicate the configurations in the molecules. 
FIGURE 6. ADDITIONAL SINGLE-ISOMER COMPOUNDS IN DEVELOPMENT AS NEW SINGLE-ISOMER CHEMICAL ENTITIES
The letters D, L, R and S indicate the configurations in the molecules. levels of total and low-density lipoprotein (LDL) cholestero l and increasing levels of high-density lipoprotein (HDL) chol e s t e rol. Rosuvastatin was effective both in patients with hete rozygous familial hyperc h o l e s t e rolemia and in patients with p r i m a ry hyperc h o l e s t e ro l e m i a .
A diff e rent approach to the reduction of cholesterol levels is taken with another single-isomer drug candidate, ezetimibe (SCH48461, Figure 4) . The drug molecule contains the (for c a rdiovascular drugs) unusual β-lactam ring (the four-m e mb e red nitrogen-containing ring in the stru c t u re in Figure 4 ) characteristic of penicillins and cephalosporins. Ezetimibe acts by inhibiting the intestinal absorption of cholesterol, and in Phase II studies 2 8 m o re than 50% of patients receiving the d rug as monotherapy achieved a >15% reduction in LDL c h o l e s t e rol, while in 15% of the patients the reduction was at least 25%. Intere s t i n g l y, in animal models the phenolic gluc u ronide metabolite of ezetimibe was found to be 400 times m o re potent than the parent drug as an inhibitor of intestinal c h o l e s t e rol absorption. 2 9 Anti-infective therapy is also a field of intense dru g -d e v e lopment activities, and, not surprisingly, a number of singleisomer candidates are in development in this area. For example, posaconazole (SCH56592, Figure 5 ) is a new antifungal candidate. The compound is a synthetic product, and it is interesting to note that based on its chemical stru c t u re (four chiral centers, see Figure 5 ), it is a single isomer out of 16 possible stereoisomers, attesting to the power of synthetic o rganic chemistry. Posaconazole is an "azole" type antifungal containing the triazole moiety ( Figure 5 ) that binds to the active-site heme group of a fungal CYP. Such binding re s u l t s in the inhibition of the enzyme which in turn is the mechanism of antifungal action of azoles. The drug is a bro a d -s p e ct rum antifungal, The antiviral agent (-)-β-D-2,6-diaminopurine (DAPD, F i g u re 5) is a nucleoside reverse-transcriptase inhibitor with activity against the human immunodeficiency viru s ( H I V-1 ) 3 4 , 3 5 and against hepatitis B viru s . 3 5 The drug is actually a pro d rug and is rapidly converted by adenosine deaminase to (-)-β-dioxolane guanine 3 4 , 3 5 (DXG, Figure 5 ). In H I V-infected subjects a majority of the DAPD absorbed is metabolized to DXG and the plasma levels reached by DXG indicate that it is the active anti-HIV compound.
3 6 Also, in these patients the plasma half-life of DXG is considerably longer than that of DAPD. 3 6 Many other NSICE drug candidates in a variety of other therapeutic areas are also in development. For example a p repitant (L-754,030 and MK-0869, Figure 6 ) is an inhibitor of the substance P-pre f e rring NK1 re c e p t o r.
3 7 S u c h substance P antagonists have been proposed for the therapy of chronic pain, emesis, and depre s s i o n . 3 8 I n t e re s t i n g l y, h o w e v e r, while efficacy in depression and emesis is conf i rm e d , 3 7 -3 9 their ability to alleviate pain has been re c e n t l y q u e s t i o n e d . 3 8 , 4 0 At any rate, aprepitant is in development as an intravenous agent for the treatment of migraine and c h ronic pain and as an antiemetic. Since the drug has insufficient water solubility, a phosphoramidate derivative ( L -758,298; Figure 6 ) was synthesized as a water-s o l u b l e p ro d rug of apre p i t a n t .
3 7 , 4 1 I n t e re s t i n g l y, the pro d rug was stable in human blood in vitro, but was rapidly converted to a p repitant in human liver micro s o m e s . 4 1 P regabalin ( Figure 6 ) is a 3-substituted GABA analog related to the anticonvulsant agent gabapentin. As seen in F i g u re 6, the molecule is a single isomer of very simple stru ct u re. The drug was originally developed as an antiepileptic 4 2 , 4 3 but subsequently it became clear that this agent might be useful in other indications, eg, in pain and in behavioral diso rd e r s , 42, 44 and the drug is now in development for pain in diabetic neuro p a t h y, migraine, and social phobias.
It was predicted recently that a boom in peptide drugs is in the making. 45 Among the reasons for this prediction are the many new biological targets being identified, improved manufacturing methods for peptides, and the development of new d e l i v e ry systems. 4 5 Indeed, it is already clear that many peptide drug candidates are in development. 4 5 One example is a b a relix (Figure 6 ), a decapeptide that is a single isomer out of a possible 1024 stereoisomers. Several of the amino acid moieties in the molecule are synthetic rather than naturally o c c u rring, and five of the amino acids are in the unnatural D configuration (Figure 6 ). Abarelix is a LHRH receptor antagonist in development for prostate cancer and endometriosis. 4 6 As of this writing, a new-drug application (NDA) for a depot dosage form of abarelix in the treatment of prostate cancer is under review by the FDA.
C O N C L U S I O N
Nearly all new drug candidates based on chiral molecules a re being developed in single-isomer form rather than the racemate, and basic pharmacological considerations suggest that the single-isomer form is preferable in most cases. The new single-isomer agents now in advanced development encompass a large variety of chemical stru c t u res and therapeutic indications. It is clear that a new age of single-isomer therapeutics has dawned. C N S
